Monopar Therapeutics' mission is developing innovative drugs and drug combinations to improve clinical outcomes in advanced cancer.

Monopar is building a drug development pipeline through the licensing or acquisition of oncology therapeutics at the late preclinical through advanced clinical development stage that have demonstrated good antitumor efficacy and safety when used in combination, de-risking clinical development.

To contact Monopar about a potential partnership, collaboration, or licensing opportunity, please contact info@monopartx.com.